TNF and rheumatoid arthritis: The identification of tumour necrosis factor-alpha (TNF-α) as a key mediator of inflammation in RA has led to the development of TNF-α-blocking biologics that control disease activity, but there remains a need for therapies capable of modulating the underlying immune response [4].